MHE September 2026

The FDA approved July 2026 Simtriyo, a new type of medication for patients with attention-deficit hyperactivity disorder (ADHD).

As artificial intelligence agents learn to improve autonomously, the humans who must use and regulate such tools find themselves behind the curve.

Funding from the Rural Health Transformation Program is beginning to flow to the states. The purpose is larger, but some say its success should be measured by whether it preserves access to care at rural hospitals.

Christine M. Lovly, M.D., Ph.D., of City of Hope, and Alice Shaw, M.D., Ph.D., of Dana-Farber Cancer Institute, discussed the seven-year follow-up results from the phase 3 CROWN trial in a "Between the Lines" video series.

Argentina's healthcare trade-offs are playing out in real time. U.S. leaders should be paying attention.